Related Experiment Video
Updated: Jul 4, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Maximizing dendritic cell migration in cancer immunotherapy
Pauline Verdijk1, Erik H J G Aarntzen, Cornelis J A Punt
1Radboud University Nijmegen Medical Centre, Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Geert Grooteplein 28, Nijmegen, The Netherlands.
Background:
The success of dendritic cell (DC)-based immunotherapy in inducing cellular immunity against tumors is highly dependent on accurate delivery and trafficking of the DC to T-cell-rich areas of secondary lymphoid tissues.
Objective:
To provide an overview of DC migration in vivo and how migration to peripheral lymph nodes might be improved to optimize DC therapy.
Methods:
We focused on DC migration in preclinical models and human skin explants and on clinical vaccination trials studying migration of in vitro-generated DC.
Results/Conclusions:
DC migration requires an intricate interplay between the cell and its environment. To maximize migration for cellular therapy, it is important to optimize the generation of migratory DC as well as treatment strategies.
Related Concept Videos
Tumor Immunotherapy
Chemotaxis and Direction of Cell Migration
Cancer Cell Migration through Invadopodia
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

